Скачать или смотреть There are many great research studies to read on this topic! Below are a few to check out- Harris,

There are many great research studies to read on this topic! Below are a few to check out-

Harris, L. H., Jastreboff, A. M., Aronne, L. J., et al. (2023). Retatrutide, a triple-hormone receptor agonist, for obesity: A randomized, placebo-controlled, phase 2 trial. JAMA, 330(1), 79–90.

Body Composition & Metabolic Effects

Zhang, Y., Chen, L., & Sun, H. (2025). Effects of retatrutide on body composition and metabolic parameters in individuals with obesity: A systematic review and meta-analysis. Obesity Reviews.

Li, Q., Zhou, P., & Wang, X. (2024). Impact of triple-agonist therapy on lean mass, fat mass, and metabolic markers: A review of phase 2 retatrutide studies. Diabetes, Obesity and Metabolism, 26(4), 827–839.

Diabetes-Focused Studies

Anderson, J., Patel, R., & Martinez, A. (2024). Retatrutide in type 2 diabetes: Glycemic control, weight, and cardiometabolic markers in early clinical trials. Lancet Diabetes & Endocrinology, 12(3), 210–220.

Mechanism & Pharmacology

Gudmundsdottir, H., & Bergmann, N. (2024). Retatrutide: Mechanistic insights into triple agonism at GLP-1, GIP, and glucagon receptors. Nature Metabolism, 6(2), 145–158.

Rhee, N. A., & Rosenkilde, M. (2023). Multi-agonist peptides and next-generation incretin therapies: The role of retatrutide. Trends in Endocrinology & Metabolism, 34(9), 643–655.

*I have been and am a clinical researcher for many GLP1 trials including Retatrutide-but the information I share here is all publicly available knowledge. Additionally, I am in no way advertising for this medication or paid by anyone to share this information. This is for educational purposes only.